SCHEMBL5170508

SCHEMBL5170508

CC(=O)NC1(c2cccc(F)c2)CCNCC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
CYP2C19 P33261 4/20 0.58
HTT P42858 2/20 0.55
GAA P10253 1/20 0.55
USP2 O75604 2/20 0.44
CYP2D6 P10635 2/20 0.44
ALOX15 P16050 1/20 0.44
BACE1 P56817 1/20 0.44
HDAC3 O15379 5/20 0.43
HDAC1 Q13547 5/20 0.43
HDAC2 Q92769 5/20 0.43
HDAC6 Q9UBN7 5/20 0.43
TACR3 P29371 1/20 0.43
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP3A4 P08684 1/20 0.40
AKT1 P31749 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL3894178 0.95 ALDH1A1 (0.54) ALDH1A1CYP2C19HTTGAAUSP2
SCHEMBL19280073 0.83 ALDH1A1 (0.41) ALDH1A1CYP2C19HTTGAABACE1
SCHEMBL5168073 0.83 CCR2 (0.46) ALDH1A1CYP2C19HTTGAABACE1
SCHEMBL9910969 0.82 ALDH1A1 (0.66) ALDH1A1CYP2C19HTTGAACYP2D6
SCHEMBL2231946 0.82 POLB (0.57) ALDH1A1CYP2D6ALOX15HDAC1POLB
SCHEMBL5169982 0.82 CYP2C19 (0.44) ALDH1A1CYP2C19HTTGAAHDAC3
Hydrochloric Acid SCHEMBL2479293 0.81 POLB (0.56) ALDH1A1CYP2D6ALOX15HDAC1POLB
Formic Acid SCHEMBL3899780 0.79 BACE1 (0.44) ALDH1A1CYP2C19HTTGAABACE1
SCHEMBL3894181 0.78 ALDH1A1 (0.43) ALDH1A1CYP2C19HTTGAAUSP2
Formic Acid SCHEMBL3898641 0.77 CYP2C19 (0.41) ALDH1A1CYP2C19HTTGAAHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10414771-B2 Compounds useful for inhibiting metastasis from cancer and methods using same DREXEL UNIVERSITY (US) 2019-09-17 US disclosed
US-20180099972-A1 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same UNIV DREXEL (US) 2018-04-12 US disclosed
EP-1773823-B1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-08-21 EP disclosed
EP-1773823-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-04-18 EP disclosed
WO-2006021654-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099972-A1 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same CX3CR1, CCL2, CCR5 ALDH1A1 927/4885CYP2C19 1823/4885HTT 2506/4885
US-10414771-B2 Compounds useful for inhibiting metastasis from cancer and methods using same CX3CR1, CCL2, CCR5 ALDH1A1 927/4885CYP2C19 1823/4885HTT 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.